ABcann Medicinals Inc. Hosts Cannabinoids Lecture by The Father of Medical Marijuana Research

NAPANEE, ON / ACCESSWIRE / June 24, 2015 / ABcann Medicinals Inc. has teamed up with Queen’s University to host The Cannabinoids: Looking Back and Ahead on June 25, 2015, presented by Professor Raphael Mechoulam, the world’s leading expert in medical cannabis research. The lecture is part of the School of Medicine’s Department of Biomedical and Molecular Sciences Plenary Lecture Series.

The lecture will cover the development of the cannabinoid field with an overview of the research and involvement of Professor Mechoulam from 1964 to present day, along with investigations on the involvement of endocannabinoids in biological processes and as potential drugs. Attendees will also have the opportunity to discuss cannabis and all of its medicinal properties.

Professor Mechoulam, also known as the “Father of Medical Marijuana,” is the Israeli Organic Chemist that determined the structure of cannabidiol (CBD) and was able to isolate and synthesize tetrahydrocannabinol (THC). By 1992, he was also able to isolate and elucidate the structure of the brain’s first endogenous cannabinoid, Anandamide. Since then, Professor Mechoulam has become crucial in the ongoing research on medical cannabis and its relationship with memory, appetite and pain.

By engaging the medical and academic research community, ABcann will provide physicians with the latest, ongoing information to build confidence needed to discuss and prescribe medical cannabis to their patients. With the growing number of patients (20,277 registered as per Health Canada’s latest market data) it becomes increasingly important to educate physicians on medical cannabis to ensure best and safe practices.

The lecture will also be broadcast online for the public at: http://meds.queensu.ca/live.

About ABcann Medicinals Inc.

ABcann Medicinals Inc. is an approved Licensed Producer under the Marihuana for Medical Purposes Regulations (MMPR). We believe the success of the pharmaceutical industry was based on their ability to manufacture medicine achieved through methods of precision, quality controls, high standards and good manufacturing practices. ABcann has structured our vision to align with these principles. We’ve developed a system capable of producing standardized chemical compounds derived from plants. This unique technology sets us apart from the traditional competitors in the cannabis industry. Experts agree this is the only way to grow plants to be accepted as medicine.

Professor Raphael Mechoulam states:

“Your effort to have Cannabis crops fully standardized from batch to batch moves Cannabis treatment closer to the drug standards generally accepted by physicians and patients and represents an important and very valuable step.”

Visit www.abcann.ca and @abcannmed for more information.

For more information about The Cannabinoids: Looking Back and Ahead or ABcann Medicinals Inc., please contact:

ABcann Medicinals Inc.
info@abcann.ca
1-855-322-2266

Anna Campbell
Argyle Public Relationships
acampbell@argylepr.com
416-968-7311 ext. 247

SOURCE: ABcann Medicinals Inc.

ReleaseID: 430071